Why iTeos Therapeutics Shares Are Surging Today

iTeos Therapeutics Inc ITOS shares are trading higher by 36.7% at $27.38 Monday afternoon after the company and GlaxoSmithKline announced an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody.

See Also: iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.